(R)-N-1-Boc-N-4-Cbz-2-哌嗪甲酸 | 138775-02-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-N-1-Boc-N-4-Cbz-2-哌嗪甲酸
• 中文别名: (2R)-4-[(苄氧基)羰基]-1-(叔丁氧基羰基)哌嗪-2-羧酸
• 英文名称: (2R)-4-[(benzyloxy)carbonyl]-1-[(tert-butoxy)carbonyl]piperazine-2-carboxylic acid
• 英文别名: (R)-4-((benzyloxy)carbonyl)-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid；4-[(benzyloxy)carbonyl]-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid；(2S)-4-benzyloxycarbonyl-1-tert-butoxycarbonylpiperazine-2-carboxylic acid；1-Boc-4-Cbz-piperazine-2(R)-carboxylic acid；(2R)-1-[(tert-butyl)oxycarbonyl]-4-[benzyloxycarbonyl]piperazine-2-carboxylic acid；(2R)-4-[(benzyloxy)carbonyl]-1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid；(2R)-1-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenylmethoxycarbonylpiperazine-2-carboxylic acid
• CAS: 138775-02-7
• 化学式: C₁₈H₂₄N₂O₆
• 分子量: 364.398
• InChiKey: SREPAMKILVVDSP-CQSZACIVSA-N

物化性质

• 密度：
  1.272

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  96.4
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8℃，干燥密封保存

反应信息

• 作为反应物：
  描述：

  (R)-N-1-Boc-N-4-Cbz-2-哌嗪甲酸 在 盐酸 、 palladium on carbon 、 氢气 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-N1-(2,3-dichlorophenyl)-N3-((1R,2S)-2-phenylcyclopropyl)piperazine-1,3-dicarboxamide
  参考文献：
  名称：

  Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, Part 2

  摘要：

  The Hedgehog (Hh-) signaling pathway is a key developmental pathway which gets reactivated in many human tumors, and smoothened (Smo) antagonists are emerging as novel agents for the treatment of malignancies dependent on the Hh-pathway, with the most advanced compounds demonstrating encouraging results in initial clinical trials. A novel series of potent bicyclic hydantoin Smo antagonists was reported in the preceding article, these have been resolved, and optimized to identify potent homochiral derivatives with clean off-target profiles and good pharmacokinetic properties in preclinical species. While showing in vivo efficacy in mouse allograft models, unsubstituted bicyclic tetrahydroimidazo[1,5-a]pyrazine-1,3(2H,5H)-diones were shown to epimerize in plasma. Alkylation of the C-8 position blocks this epimerization, resulting in the identification of MK-5710 (47) which was selected for further development. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.023
• 作为产物：
  描述：

  氯甲酸苄酯 在 乙二胺四乙酸 、 copper diacetate 、 potassium carbonate 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 50.67h， 生成 (R)-N-1-Boc-N-4-Cbz-2-哌嗪甲酸
  参考文献：
  名称：

  哌嗪类新型细菌拓扑异构酶抑制剂的固相合成及生物学评价

  摘要：

  全球迫切需要新的更有效的抗生素来对抗多重耐药菌。这种情况导致了针对重要细菌酶 DNA 促旋酶和拓扑异构酶 IV 的新型细菌拓扑异构酶抑制剂 (NBTI) 的大规模工业研究。然而，一些 NBTI 化合物类别与抑制 hERG 钾通道有关，hERG 钾通道是心律失常的不良原因，通过漫长的合成路线挑战药物化学工作。我们在此提出了一种固相策略，可快速促进一类有前途的新型 NBTI 的化学合成。合成了一个概念验证文库，该文库能够通过支架替代调节 hERG 亲和力和抗菌活性。

  DOI：

  10.1016/j.bmcl.2021.128499

文献信息

• [EN] Pan-Tropic Entry Inhibitors<br/>[FR] INHIBITEURS D'ENTRÉE PANTROPIQUE
  申请人：UNIV EMORY

  公开号：WO2019183133A1

  公开（公告）日：2019-09-26

  This disclsore relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.

  本公开涉及按照式(I)的化合物、盐、前药和含有该化合物的药物配方，用于治疗与CXCR4和CCR5相关的疾病。这些疾病可能包括病毒感染、异常细胞增殖、视网膜退化和炎症性疾病，或者这些化合物可以用作免疫刺激剂或免疫抑制剂。此外，这些化合物可以与另一种来自抗病毒药物或化疗药物的活性成分结合使用。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2018006063A1

  公开（公告）日：2018-01-04

  Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides conjugated to one or more monosaccharide or oligosaccharide moieties. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

  用于治疗细菌感染的组合物和方法包括含有环七肽二聚体与一个或多个单糖或寡糖基团结合的化合物。特别是，这些化合物可用于治疗由革兰氏阴性细菌引起的细菌感染。
• [EN] INHIBITORS OF TRPC6<br/>[FR] INHIBITEURS DE TRPC6
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2019158572A1

  公开（公告）日：2019-08-22

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药用盐，其中R1至R6，A，U，V，W，X，Y和Z如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• Piperazine compounds as inhibitors of MMP or TNF
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06333324B1

  公开（公告）日：2001-12-25

  A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R1 is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R2 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R3 is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substitued lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substitued amino; R4 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R10 is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP- or TNF&agr;-mediated diseases.

  式(I)化合物，其中A为磺酰基或羰基；R1为任选取代的芳基、任选取代的杂环基团、任选取代的低级烷基或任选取代的低级烯基；R2为氢、任选取代的低级烷基、任选取代的芳基或任选取代的杂环基团；R3为任选取代的低级烷基、任选取代的低级烷氧基、任选取代的芳氧基、任选取代的低级烯基、任选取代的芳基、任选取代的杂环基团或任选取代的氨基；R4为氢、任选取代的低级烷基、任选取代的芳基或任选取代的杂环基团；R5为氢、任选取代的低级烷基、任选取代的芳基或任选取代的杂环基团；R10为羟基或保护的羟基，及其药学上可接受的盐。本发明的化合物作为药物，用于预防和治疗MMP或TNFα介导的疾病。
• [EN] PYRIDINE CARBONYL DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE CARBONYLE ET LEURS UTILISATIONS THÉRAPEUTIQUES EN TANT QU'INHIBITEURS DE TRPC6
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2019081637A1

  公开（公告）日：2019-05-02

  The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  该发明涉及式(I)的化合物及其药用盐，其中R1至R7，A，Y和L的定义如本文所述。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。